Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka,Dr Vadratsikas

Our institutional guidelines discussed Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

The first successful trial in steroid refractory GVHD. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

We discussed a case of CNS lymphoma and the diffrent HD regimens. we favour regimens with Rituxmab, Thiotepa and bu or AraC   R-Busulfan-thiotepa Rituximab -6 Busulfan 2 days -5, -4 Thiotepa 5 mg/kg days -4 and -3   (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5473-z)   Other regimens Regimen without Thiotepa BUCYE Busulfan 3.2 mg/kg days...

We discussed the current EBMT guidelines for COVID19. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

The current Indications for HCT were discussed. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

This cohort analysis evaluates theincidence, risk factors and mortality of pre-engraftment blood-stream infections(BSIs) and ds-DNAviral infections (VIs) after HSCTwith post-transplant cyclophosphamide(PT-Cy) platform among different donor sourcesAllogeneic HSCT with PT-Cy showed a 32% incidence of pre-engraftment BSIsand donor type did not affect their occurrence·VIsare common in early...

Even at low doses, nivolumab maintenance after allo-SCT can cause serious immune-related toxicitiesWe report rapid, unexpected occurrences of grade 3/4 immune-related adverse events ·Nivolumab enhanced the graft-vs-tumor response but more studies are needed to improve tolerability Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

An excellent overview. We discusssed the differences betwen current used flt3 inhibitors. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

An article published in BMT suggest that PT/Cy-haplo recipients may  reconstitute CMV-specific T-cell immunity to the same extent as patients  undergoing HLA-matched allo-HSCT Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Results of the international MRC UKALLXII/ECOG E2993 trial. Out of the  1 752 patients who achieved CR, 11·7% underwent autologous and 40·6%  allogeneic transplant, while in CR1. Of the autologous patients, 43·2%  relapsed early and 3·4% relapsed late. However, among the allogeneic  patients, 13·2% relapsed early and only 1·3%...

Excellent review. The most of the newly approved drugs are for pts >75  years. The "problems"  of the approval trials are discussed. AS the  authro points: Don’t trust the horse, Trojans. Whatever it is, I fearthe Greeks even  bearing gifts.)—Virgi Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou,...

A combination of phenotypic and functional immune assays enables risk-stratification of patients with viral infections after transplantFunctional immune monitoring can help identify patients in need of additional antiviral intervention Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

A retrospective study, The combination of thiotepa, busulfan fludarabine (TBF) reduces the risk of relapse in patients with remission AML, as compared to myeloablative busulfan fludarabine (BUFLU)The effect is independt of donor type and GvHD prophylaxis. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas